TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10447629
Drug: Classic nail
Normalized name: FUNGI NAIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic nail (intramedullary implant) for fixation of peritrochanteric fractures
Study: 1693762
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg and 10 mg of heroin
Study: 1693762
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg and 2 mg of hydromorphone
Study: 1693762
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of the same drug
Study: 1693762
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of the alternate drug
Study: 1693762
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (heroin and hydromorphone)
Study: 489201
Drug: Metoprolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 40 mg orally
Study: 30359681
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneously every 4 weeks plus standard of care
Study: 23498594
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCSs) treatment during acute LRTIs, n = 70
Study: 23498594
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with OCSs during acute LRTIs, n = 42
Study: 23498594
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids (OCSs) treatment during severe LRTIs, n = 133 (from the second cohort)
Study: 15293971
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg as a single dose)
Study: 15293971
Drug: Mebendazole (Janssen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (Janssen, 100 mg twice a day for three days)
Study: 15293971
Drug: Mebendazole (Unibios,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (Unibios, 100 mg twice a day for three days)
Study: 15293971
Drug: Mebendazole (East
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (East African Pharmaceuticals, 100 mg twice a day for three days)
Study: 11444712
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine/prilocaine) applied 45 minutes before intravenous cannulation
Study: 11444712
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied 45 minutes before intravenous cannulation
Study: 335516
Drug: Cranial irradiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation plus intrathecal therapy during early remission
Study: 335516
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methotrexate in combination drug treatment
Study: 27709313
Drug: DA-3031 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-3031 (6 mg on day 2 of each chemotherapy cycle)
Study: 27709313
Drug: Filgrastim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (100 μg/m2/day for up to 10 days)
Study: 23616163
Drug: Low-dose propranolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propranolol (20 mg)
Study: 23616163
Drug: High-dose propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propranolol (80 mg)
Study: 21672315
Drug: tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.2 mg orally once daily for 4 weeks
Study: 21672315
Drug: silodosin 4
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: silodosin 4 mg orally twice daily for 4 weeks
Study: 19114862
Drug: tipranavir/ritonavir (TPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tipranavir/ritonavir (TPV/r) 500/200 mg twice daily (b.i.d.)
Study: 12590854
Drug: 4% boric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% boric acid solution in alcohol and frequent suction cleaning of the ear canal
Study: 12590854
Drug: tioconazole ointment
Normalized name: TIOCONAZOLE 65 mg in 1 g VAGINAL OINTMENT [TIOCONAZOLE OINTMENT 6.5%]
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tioconazole ointment
Study: 10487457
Drug: BMV lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMV lotion
Study: 7202249
Drug: Trimethoprim (TMP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (TMP), 300 mg once a day for seven days (group 1)
Study: 7202249
Drug: Trimethoprim (TMP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (TMP), 200 mg once a day for 10 days (group 2)
Study: 7202249
Drug: Nitrofurantoin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin, 100 mg four times a day for 10 days (group 3)
Study: 18773686
Drug: Conservative drug
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative drug therapy + Su Jok therapy with laser ray at acupuncture points
Study: 21478141
Drug: Conservative drug
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative drug therapy only
Study: 16216060
Drug: Azosemide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azosemide (30 mg/d for cardiac/renal edema; 60 mg/d for hepatogenic edema)
Study: 16216060
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg/d for cardiac/renal edema; 40 mg/d for hepatogenic edema)
Study: 14693730
Drug: Total testosterone:sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total testosterone:sex hormone binding globulin ratio
Study: 10507606
Drug: Fenoldopam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 0.03 µg/kg/min
Study: 10507606
Drug: Fenoldopam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 0.1 µg/kg/min
Study: 10507606
Drug: Fenoldopam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam 0.3 µg/kg/min
Study: 7138727
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam alone
Study: 7138727
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam with atropine
Study: 7138727
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam with hyoscine
Study: 31852287
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) plus 25 µg sublingual misoprostol
Study: 27684379
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment for patients with two consecutive viraemia episodes below 3000 genomes/ml
Study: 27684379
Drug: Monitoring for
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitoring for patients with two consecutive viraemia episodes below 3000 genomes/ml
Study: 27684379
Drug: Stopping treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping treatment when viraemia is less than 200 genomes/ml
Study: 27684379
Drug: Stopping treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping treatment when viraemia is less than 3000 genomes/ml
Study: 18753005
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of tricyclic antidepressants (TCAs)
Study: 18753005
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of selective serotonin reuptake inhibitors (SSRIs)
Study: 1755638
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment for covert bacteriuria for the first four years
Study: 6352366
Drug: pirprofen 400
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pirprofen 400 mg b.i.d.
Study: 6352366
Drug: indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 50 mg b.i.d.
Study: 29729427
Drug: Prednisolone (PRED)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PRED) 7.5 mg once daily (n=12)
Study: 29729427
Drug: Prednisolone (PRED)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PRED) 30 mg once daily (n=12)
Study: 30496870
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated hepatitis A vaccine (HA-L)
Study: 30496870
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (HA-I)
Study: 20442102
Drug: Tumescence treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescence treatment
Study: 20442102
Drug: Cannulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannulation treatment
Study: 12168923
Drug: Octreotide 600-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 600-800 microg/day and chlorpromazine (15-25 mg/day)
Study: 12168923
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide 60-80mg/day and chlorpromazine (15-25 mg/day)
Study: 8583349
Drug: Pressurized metered‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered‐dose aerosol inhaler (125 micrograms per dose)
Study: 8583349
Drug: Novel mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel mechanical pump spray device (500 micrograms per dose)
Study: 2714067
Drug: Clindamycin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (900 mg Q8H) and Gentamicin (3-5 mg/kg/day in divided doses Q8H)
Study: 788731
Drug: Indomethacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (200 mg daily)
Study: 19427180
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection (DHI) administered intravenously
Study: 12934420
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (2 mg/kg) administered 1 min before intubation
Study: 12934420
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (2 mg/kg) administered 3 min before intubation
Study: 12934420
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (2 mg/kg) administered 5 min before intubation
Study: 12934420
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (2 mg/kg) administered 10 min before intubation
Study: 11128559
Drug: Amoxycillin 45
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 45 mg/kg/day b.d.
Study: 11128559
Drug: Amoxycillin 40
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 40 mg/kg/day t.d.s.
Study: 9129069
Drug: Ganciclovir 8
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir 8 mg/kg/day
Study: 9129069
Drug: Ganciclovir 12
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir 12 mg/kg/day
Study: 7949548
Drug: Serum creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum creatinine < 1.7 mg/dl at the time of steroid withdrawal
Study: 3668883
Drug: GSR biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSR biofeedback training (minimally effective treatment control)
Study: 31840339
Drug: FITNET-NHS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FITNET-NHS treatment
Study: 29989107
Drug: 6‐mm implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mm implants (experimental)
Study: 29989107
Drug: 10‐mm implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mm implants with vertical augmentation (control)
Study: 28963315
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard therapy
Study: 23545101
Drug: Intravesical gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical gemcitabine (2,000 mg/50 cc weekly for 6 weeks, maintenance monthly for 1 year)
Study: 23545101
Drug: 1/3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/3 dose Bacillus Calmette‐Guérin (weekly for 6 weeks, maintenance 3 weekly instillations at 3, 6 and 12 months)
Study: 19553063
Drug: Behavioral couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral couples therapy (BCT) plus individual‐based treatment (IBT)
Study: 19553063
Drug: Individual‐based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual‐based treatment (IBT) only
Study: 16423517
Drug: Puffs of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puffs of beta 2 agonist (salbutamol 50 microg/kg or terbutaline 125 microg/kg) via spacer
Study: 9264427
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (6 g/day for 3 days)
Study: 8908436
Drug: Ciprofloxacin ophthalmic
Normalized name: ciprofloxacin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin ophthalmic solution 0.3%
Study: 8353434
Drug: Chloramphenicol ophthalmic
Normalized name: chloramphenicol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol ophthalmic solution 0.5%
Study: 28771070
Drug: Office-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based physical therapy (OBPT)
Study: 23321194
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg orally 2 hours before surgery
Study: 18195263
Drug: [(18)F]fluoro‐l‐dopa uptake
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(18)F]fluoro‐l‐dopa uptake in TLE patients
Study: 18195263
Drug: Glucose metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose metabolism assessment in TLE patients
Study: 10824634
Drug: Low-dose pirenzepine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pirenzepine (0.5 mg intravenous bolus followed by continuous infusion of 0.15 microg/kg/min)
Study: 10824634
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine treatment
Study: 8420815
Drug: Picotamide (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (900 mg/day) in normal subjects
Study: 20875504
Drug: Action observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action observation treatment (AOT) in addition to conventional physiotherapy
Study: 12720616
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler training
Study: 1844694
Drug: Component therapies
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component therapies
Study: 26906713
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR 40 mg and 60 mg
Study: 27423779
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel 120 mg
Study: 20681235
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CMG)
Study: 15598196
Drug: Methadone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone plus injectable heroin or methadone plus inhalable heroin prescribed over 12 months (heroin maximum 1000 mg per day, methadone maximum 150 mg per day)
Study: 15598196
Drug: Heroin-assisted treatment
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin-assisted treatment (previously participated in abstinence-oriented treatment)
Study: 15598196
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment (previously participated in abstinence-oriented treatment)
Study: 15598196
Drug: Heroin-assisted treatment
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin-assisted treatment (no experience in abstinence-oriented treatment)
Study: 15598196
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment (no experience in abstinence-oriented treatment)
Study: 11051015
Drug: Low-dose ESWT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ESWT (3 x 5000 impulses, no anesthesia)
Study: 11051015
Drug: High-dose ESWT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ESWT (1 x 5000 impulses, intravenous analgesia)
Study: 19517101
Drug: CPG-DDS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG-DDS plus 1 mg/kg/day artesunate
Study: 19517101
Drug: CPG-DDS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG-DDS plus 2 mg/kg/day artesunate
Study: 19517101
Drug: CPG-DDS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPG-DDS plus 4 mg/kg/day artesunate
Study: 19517101
Drug: CPG-DDS alone
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPG-DDS alone (2/2.5 mg/kg/day)
Study: 17355738
Drug: Rivastigmine treatment
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine treatment (3 mg/day to 9 mg/day over time)
Study: 17355738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained on current antipsychotic medication)
Study: 7523735
Drug: Prostate cancer
Normalized name: Leuprolide Acetate 22.5mg Lyophilisate for suspension for injection [Prostate Cancer] with Diluent, Transfer Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate cancer screening using prostate specific antigen and digital rectal examination
Study: 26591681
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment 1 and 2
Study: 26591681
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment 1 and 2
Study: 20349353
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving cancer treatment
Study: 20349353
Drug: Patients awaiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients awaiting new treatment
Study: 20349353
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on surveillance or whose treatment had been stopped
Study: 19004162
Drug: Weight-loss supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-loss supplement
Study: 19004162
Drug: Both supplement
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both supplement and coaching
Study: 12212248
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume ventilation (tidal volume 6-8 ml.kg-1)
Study: 12212248
Drug: Normal volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal volume ventilation (tidal volume 12-14 ml.kg-1)
Study: 8941026
Drug: Didanosine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (300 mg) administered orally and intravenously
Study: 8941026
Drug: Didanosine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (300 mg) administered orally 4 hours before hemodialysis
Study: 14621771
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 10 mg/kg per day
Study: 3932470
Drug: Dobutamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusions
Study: 14671236
Drug: Saline infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusions (control)
Study: 27062041
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (250 mg)
Study: 22812731
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airways pressure treatment for patients with obstructive sleep-disordered breathing (apnea hypopnea index ≥20)
Study: 22812731
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airways pressure treatment
Study: 19266407
Drug: Bonding social
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonding social capital (treatment and emotional buddy)
Study: 16114155
Drug: Crinone gel
Normalized name: Crinone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Crinone gel (n=36)
Study: 11799502
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine with 2 microg/mL fentanyl (group RF, n = 20)
Study: 1941733
Drug: Rioprostil, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil, 300 micrograms twice daily for 12 weeks
Study: 28407735
Drug: Telbivudine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine treatment starting at 12 weeks (Group A; n=62)
Study: 28407735
Drug: Telbivudine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine treatment starting at 20-28 weeks (Group B; n=61)
Study: 28407735
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral treatment (Group C; n=65)
Study: 19852303
Drug: Guilong Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guilong Tongluo Capsule (GTC) combined with prednisone
Study: 15102339
Drug: S-adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAMe) 1200 mg